Protano has extensive operational and financial experience with 25 years of leadership experience with innovative technology and biotechnology companies
CAMBRIDGE, Mass., August 2, 2022 /PRNewswire/ — Alwaysa pioneering flagship company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and solve disease, today announced the appointment of Joanne Protano as Chief Financial Officer (CFO).
Protano most recently served as senior vice president of finance and operations at Rubius Therapeutics, a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create a new class of cellular medicines for the treatment of cancer and autoimmune diseases.
Over the past five years, he led all financial aspects of the business and built the financial and operational infrastructure to advance four programs into clinical trials, establish a clinical manufacturing facility, increase nearly 800 million dollars in capital, and evolve from a private company to a public company with a maximum market capitalization of more than 2.5 billion dollars.
“Joanne is an extraordinary leader and catalyst for the strategic growth and financing of biotech companies with transformational platforms,” he said. Michelle C. Werner, CEO-Partner, Flagship Pioneering and CEO, Alltrna. “We welcome Joanne to the Alltrna team as we build the foundation and momentum of RNA advances to boldly establish a field platform for deep and systematic exploration of the universe of “tRNA”.
“What intrigued me about Alltrna is the unparalleled potential of tRNA medicines to unify the treatment of thousands of diseases, from rare to common, with a precision medicine approach,” said Protano. “I look forward to building the strategy and financial and operational structure to support the company as Alltrna unlocks the nearly limitless potential of tRNA medicines.”
about Joanne Protano
Prior to Rubius, Protano was Senior Vice President of Finance, New Ventures at Flagship Pioneering, where he provided financial and operational oversight to several early-stage Flagship portfolio companies. Prior to Flagship, she served as CFO of Novelos Therapeutics, a public biotechnology company developing drugs for the treatment of cancer. Previously, Protano held several senior finance roles with Ascential Software and predecessor companies and began his career in Deloitte & Touche LLP’s assurance practice. He has a degree in business administration Bryant University and is a certified public accountant.
About Alltrna
Alltrna unlocks tRNA biology to correct disease. The company’s platform incorporates AI/ML tools to learn the tRNA language and deliver various programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA drug to unify treatment across a wide range of diseases with the same underlying genetic mutation. Alltrna was founded in 2018 by Flagship Pioneering. For more information, visit www.alltrna.com.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources and develops world-class bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm, through its Flagship Labs unit, has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than 100 billion dollars in aggregate value. So far, Flagship has been deployed 2.9 billion dollars in capital towards the foundation and growth of its pioneering companies alongside more than 19 billion dollars of subsequent investments by other institutions. The current flagship ecosystem includes 41 transformative companies, including Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: mRNA), Omega Therapeutics (NASDAQ: OMG), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: A LOT), and Seres Therapeutics (NASDAQ: MCRB).
Media contact for Alltrna
Jessica YinglingPh.D., Little Dog Communications Inc., [email protected]+1.858.344.8091
Other SOURCE
[ad_2]
Source link
